Increasing losses prompt Zephyrm Bioscience to seek funds through IPO
This biotech company, which focuses on the R&D of stem cell drugs, has filed for listing on the Hong Kong Stock Exchange, hoping to get a slice from the hot…
RECENT ARTICLES
-
CARsgen seeks cell therapy breakthrough but stays in the red for now
2171.HK - Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
- EKH turns to Hong Kong market to load up on new funds
